AGF Investments Inc. Purchases 37,165 Shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH)

AGF Investments Inc. grew its stake in shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) by 112.1% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 70,313 shares of the biopharmaceutical company’s stock after buying an additional 37,165 shares during the quarter. AGF Investments Inc. owned approximately 0.23% of GW Pharmaceuticals PLC- worth $6,157,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Trustcore Financial Services LLC raised its holdings in shares of GW Pharmaceuticals PLC- by 54.6% in the 4th quarter. Trustcore Financial Services LLC now owns 283 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 100 shares during the last quarter. CENTRAL TRUST Co raised its holdings in shares of GW Pharmaceuticals PLC- by 321.4% in the 1st quarter. CENTRAL TRUST Co now owns 295 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 225 shares during the last quarter. Eudaimonia Partners LLC acquired a new stake in shares of GW Pharmaceuticals PLC- in the 1st quarter worth about $26,000. PSI Advisors LLC acquired a new stake in shares of GW Pharmaceuticals PLC- in the 4th quarter worth about $41,000. Finally, Valeo Financial Advisors LLC raised its holdings in shares of GW Pharmaceuticals PLC- by 76.3% in the 4th quarter. Valeo Financial Advisors LLC now owns 462 shares of the biopharmaceutical company’s stock worth $48,000 after acquiring an additional 200 shares during the last quarter. 80.17% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities research analysts recently weighed in on GWPH shares. BidaskClub upgraded shares of GW Pharmaceuticals PLC- from a “sell” rating to a “hold” rating in a report on Tuesday. HC Wainwright reduced their price objective on shares of GW Pharmaceuticals PLC- from $170.00 to $161.00 and set a “buy” rating for the company in a research report on Thursday, February 27th. Cantor Fitzgerald upped their price objective on shares of GW Pharmaceuticals PLC- from $120.00 to $154.00 and gave the stock an “overweight” rating in a research report on Thursday, May 14th. Evercore ISI initiated coverage on shares of GW Pharmaceuticals PLC- in a research report on Friday, February 7th. They issued a “buy” rating and a $260.00 price objective for the company. Finally, Citigroup initiated coverage on shares of GW Pharmaceuticals PLC- in a research report on Thursday, March 5th. They issued a “buy” rating and a $192.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $182.08.

GW Pharmaceuticals PLC- stock opened at $126.92 on Friday. GW Pharmaceuticals PLC- has a twelve month low of $67.98 and a twelve month high of $187.69. The firm has a 50 day moving average price of $103.19 and a 200-day moving average price of $105.88. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.50 and a quick ratio of 5.64.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last released its earnings results on Monday, May 11th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.88) by $0.64. GW Pharmaceuticals PLC- had a net margin of 8.42% and a negative return on equity of 9.87%. The firm had revenue of $120.60 million during the quarter, compared to the consensus estimate of $84.93 million. During the same period in the prior year, the firm earned ($0.14) EPS. The company’s revenue was up 207.7% compared to the same quarter last year. On average, research analysts predict that GW Pharmaceuticals PLC- will post -1.99 EPS for the current fiscal year.

In other news, insider Douglas B. Snyder sold 3,876 shares of the stock in a transaction that occurred on Wednesday, February 26th. The shares were sold at an average price of $9.17, for a total transaction of $35,542.92. Following the completion of the transaction, the insider now directly owns 70,104 shares of the company’s stock, valued at approximately $642,853.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Chairman Geoffrey W. Dr Guy sold 600,000 shares of the stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $6.63, for a total transaction of $3,978,000.00. Following the transaction, the chairman now directly owns 6,221,521 shares of the company’s stock, valued at $41,248,684.23. The disclosure for this sale can be found here. Insiders have sold a total of 619,728 shares of company stock valued at $4,157,466 over the last three months. Insiders own 3.60% of the company’s stock.

GW Pharmaceuticals PLC- Profile

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

Featured Article: Understanding Compound Annual Growth Rate (CAGR)

Want to see what other hedge funds are holding GWPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GW Pharmaceuticals PLC- (NASDAQ:GWPH).

Institutional Ownership by Quarter for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.